Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs Tesamorelin
An educational, source-based comparison of GHRP-6 and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
GHRP-6 vs Tesamorelin — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: Growth hormone · Appetite vs Body composition.